Heart Rate Recovery in Patients With Hypertrophic Cardiomyopathy




Recovery in heart rate (HR) after exercise is a measure of autonomic function and a prognostic indicator in cardiovascular disease. The aim of this study was to characterize heart rate recovery (HRR) and to determine its relation to cardiac function and morphology in patients with hypertrophic cardiomyopathy (HC). We studied 18 healthy volunteers and 41 individuals with HC. All patients underwent clinical assessment and transthoracic echocardiography. Continuous beat-by-beat assessment of HR was obtained during and after cardiopulmonary exercise testing using finger plethysmography. HRR and power spectral densities were calculated on 3 minutes of continuous RR recordings. Absolute HRR was lower in patients than that in controls at 1, 2, and 3 minutes (25.7 ± 8.4 vs 35.3 ± 11.0 beats/min, p <0.001; 36.8 ± 9.4 vs 53.6 ± 13.2 beats/min, p <0.001; 41.2 ± 12.2 vs 62.1 ± 14.5 beats/min, p <0.001, respectively). HRR remained lower in patients at 2 and 3 minutes after normalization to peak HR. After normalization to the difference in HR between peak exercise and rest, HRR was significantly impaired in individuals with obstructive HC at 3 minutes compared with controls. HR at 3 minutes correlated with peak left ventricular outflow tract gradient (B 0.154 beats/min/mm Hg, confidence interval 0.010 to 0.299, p = 0.037) and remained a significant predictor of HRR after multivariable analysis. Spectral analysis showed a trend toward an increased low-frequency to high-frequency ratio in patients (p = 0.08) suggesting sympathetic predominance. In conclusion, HRR is impaired in HC and correlates with the severity of left ventricular outflow tract gradient. Prospective studies of the prognostic implications of impaired HRR in HC are warranted.


Heart rate recovery (HRR) after exercise is a product of vagal reactivation and sympathetic withdrawal. Impairment of HRR after cardiopulmonary exercise testing is associated with increased cardiovascular and all-cause mortalities. As patients with hypertrophic cardiomyopathy (HC) have evidence for altered autonomic function we hypothesized that HRR responses are abnormal in HC. The aim of this study was to characterize HRR responses and to determine their relation to cardiac morphology and conventional risk factors for sudden cardiac death.


Methods


The study cohort comprised 47 consecutive patients attending a dedicated cardiomyopathy clinic at the Heart Hospital, University College London Hospitals, London, UK. The study complies with the principles of Declaration of Helsinki and National Health Service research governance arrangements.


Twenty healthy volunteers with no medical conditions or family history of inherited heart disease were recruited as controls. All participants were in sinus rhythm with no concurrent diagnosis of anemia. One patient had type 1 diabetes mellitus. Two healthy controls were considered to be athletically trained based on their reported level of activity and exercise capacity (peak oxygen consumption >170% predicted) and were excluded from subsequent analysis. Six patients performed a submaximal exercise test (respiratory quotient <1.05) and were excluded.


Before exercise, all patients underwent clinical assessment using 2-dimensional transthoracic and Doppler echocardiography, 12-lead electrocardiography, and lung spirometry. All patients fulfilled current diagnostic criteria for HC based on 2-dimensional echocardiography (maximal wall thickness ≥15 mm unexplained by abnormal loading conditions).


Measurement of left ventricular maximal wall thickness (MWT), left atrial dimension, and left ventricular dimensions at end-systole and end-diastole was performed using 2-dimensional echocardiography in accordance with previously published methods. Ejection fraction was calculated using Simpson’s biplane method. Left ventricular outflow tract obstruction (LVOTO) was measured using continuous wave Doppler; LVOTO was defined as a resting left ventricular outflow gradient of ≥30 or ≥50 mm Hg on physiological provocation (Valsalva or exercise).


New York Heart Association functional class and the following risk factors for sudden cardiac death were documented: nonsustained ventricular tachycardia (NSVT; 3 or more consecutive ventricular extrasystoles at a rate of ≥120 beats/min) on ambulatory monitoring, unexplained syncope, MWT ≥30 mm, family history of sudden cardiac death, and an abnormal blood pressure response (ABPR) to exercise (systolic blood pressure <20 mm Hg).


Beta blockers and calcium channel antagonists were withheld for at least 24 hours before exercise. Two patients with nonobstructive HC in the final study cohort were on amiodarone therapy. Five patients were receiving therapy with angiotensin-converting enzyme inhibitors, and 4 patients were on diuretics. Only 1 patient with nonobstructive HC received antihypertensive therapy (angiotensin-converting enzyme inhibitor, loop diuretic, and aldosterone antagonist) on the day of the assessment. Exercise was performed in an upright position using a bicycle ergometer (ergoselect 200P; Ergoline, Germany) and a ramp protocol in a quiet air-conditioned room with an average temperature of 21°C and full resuscitation facilities. Before the test, the exercise procedure was explained, and all subjects were given the opportunity to become familiar with the technique at zero workload. Patients were instructed to pedal at a speed of 60 to 70 revolutions per minute and were encouraged to exercise to maximal capacity. Breath-by-breath gas exchange analysis was performed using a dedicated Sensormedics metabolic cart (V Max ENCORE 229 Console; Sensormedics, Viasys Healthcare, United Kingdom). Respiratory gases were sampled continuously from a mouthpiece and analyzed using an electrochemical cell oxygen analyzer and nondispersive infrared thermopile carbon dioxide analyzer. Peak oxygen consumption (VO 2 ), workload (W), and respiratory exchange ratio were recorded.


Continuous beat-by-beat assessment of heart rate was obtained using finger plethysmography (Finometer; Finapres Medical Systems, The Netherlands). This was attached to the index finger of the left hand and maintained in neutral position using a specially made splint. Output was fed into a PC running Beatscope Easy software (Finapres Medical Systems, the Netherlands). At the point of exhaustion, the workload was returned to zero, and individuals were requested to remain static in an upright position for 3 minutes. HR in recovery was analyzed as absolute HR, HR normalized to the peak HR, and HR normalized to the change in HR from baseline to peak exercise. HR at 1, 2, and 3 minutes during recovery was obtained by calculating a mean HR from 10 consecutive beats at each respective time point. Analysis was performed on the absolute HR reduction and also on the percentage HRR standardized to peak HR and change in heart rate between baseline and peak exercise.


Power spectral densities were calculated on 3 minutes of continuous RR recordings obtained during recovery using Welch, autoregressive (Levinson-Durbin algorithm), and Lomb Scargle methods. Although absolute numbers varied, trends and group differences were similar between methods. Data from the Welch method are presented. Low-frequency and high-frequency raw powers (ms 2 ) were normalized by total power after removal of the very low frequency component and were expressed as normalized units (n.u). Analysis was performed in heart rate variability (HRV) analysis software package, 1.0.1, using MATLAB 7.12 (MathWorks, Massachusetts).


After confirmation of normality, continuous variables are expressed as mean and SD, and categorical variables are shown as frequencies and percentages. Frequencies were compared using Fisher’s exact test. Comparisons between groups were performed using independent t test and analysis of variance test with post hoc (Bonferroni) analyses to identify intergroup differences. Data that were not normally distributed are expressed as median and interquartile range and analyzed using nonparametric testing.


We sought to determine the influence of demographic and disease-specific variables on HRR using 2 models. As post hoc analysis identified significant differences between controls and patients, the first model used multivariable analysis with backward elimination and pooled patient and control data to determine the relation of a diagnosis of HC, gender, age, peak HR achieved, body mass index, and oxygen consumption at peak exercise to HR at 1, 2, and 3 minutes after exercise. To assess the influence of disease-specific variables, a second model was constructed in the patient group alone. A univariable analysis of 5 clinical surrogates for disease severity—lateral E/E′, left atrial area, ejection fraction, MWT, and left ventricular outflow gradient—and their relation to HR at 1, 2, and 3 minutes after exercise was performed using linear regression. Significant predictors were then added to an analysis that included significant (p <0.05) independent predictors of HRR identified from the first model. Statistical comparisons were carried out using IBM SPSS Statistics, version 20.0 and R 2.14 ( CRAN.R-project.org ). A p value of <0.05 was considered significant in all analyses.




Results


The final study cohort consisted of 18 controls and 41 patients with HC. Characteristics of the study groups are listed in Table 1 . The control group had equal numbers of men and women, although the HC group was predominantly men. Compared with the controls, patients were older with higher body mass index and lower HR, oxygen consumption, and workload at peak exercise. Resting HR and mean arterial pressure were similar in both groups.



Table 1

Baseline characteristics and recovery results from the control and disease groups




























































































































































































































Variable Controls (n = 18) All HC (n = 41) Nonobstructive (n = 28) Obstructive (n = 13)
Men 9 36 26 11
Age (yrs) 39.7 ± 10.0 46.7 ± 13.0 47.5 ± 13.7 44.9 ± 11.8
Body mass index (kg/m 2 ) 24.1 ± 3.0 29.5 ± 5.3 29.9 ± 5.4 28.9 ± 5.3
Mean arterial blood pressure at rest (mm Hg) 90.8 ± 7.5 92.8 ± 12.7 94.3 ± 12.3 89.6 ± 13.4
Systolic blood pressure at rest (mm Hg) 120.3 ± 10.1 124.9 ± 18.5 127.7 ± 16.1 118.8 ± 22.3
Systolic blood pressure at peak (mm Hg) 165.6 ± 21.4 169.5 ± 30.2 171.4 ± 28.8 165.4 ± 33.8
Change in systolic blood pressure (mm Hg) 44.2 ± 8.1 48.2 ± 12.4 50.2 ± 10.7 44.0 ± 15.0
Active smokers 1 4 2 2
NYHA Class 1 18 22 17 5
NYHA Class 2 0 18 10 8
NYHA Class ≥3 0 1 1 0
Resting heart rate (beats/min) 80.5 ± 14.7 76.6 ± 14.51 74.6 ± 15.8 81.1 ± 10.6
Peak heart rate (beats/min) 176.8 ± 18.1 149.8 ± 21.7 148.3 ± 24.4 153.0 ± 14.7
Change in heart rate (beats/min) 96.3 ± 17.2 73.2 ± 21.4 73.8 ± 24.2 71.9 ± 14.4
Maximal oxygen consumption (ml/kg/min) 35.1 ± 8.4 23.7 ± 5.6 24.2 ± 6.1 22.5 ± 4.4
Peak workload achieved (W) 206.1 ± 73.6 143.2 ± 47.5 152.3 ± 50.9 123.5 ± 32.5
Maximal wall thickness (mm) 17 ± [14–21] 15.0 ± [13–20.5] 18 ± [16.5–21.5]
Peak left ventricular outflow tract gradient (mm Hg) 6 [4–9.75] 78 [60–100.5]
Ejection fraction (%) 67.0 ± 7.7 66.4 ± 8.6 68.2 ± 5.5
Left atrial diameter (mm) 43.7 ± 6.0 44.5 ± 6.3 41.8 ± 5
Mean heart rate at 1 minute (beats/min) 141.4 ± 24.19 124.1 ± 19.3 121.9 ± 21.5 128.9 ± 13.1
Mean heart rate reduction at 1 minute (beats/min) 35.3 ± 11.0 25.7 ± 8.4 26.4 ± 7.8 24.2 ± 9.6
Reduction of peak heart rate at 1 minute (%) 20.4 ± 6.8 17.2 ± 5.2 17.9 ± 4.8 15.6 ± 6.0
Reduction of absolute change in heart rate during exercise at 1 minute (%) 37.7 ± 13.5 36.3 ± 11.9 37.8 ± 12.3 32.9 ± 10.9
Mean heart rate at 2 minutes (beats/min) 123.2 ± 25.7 113.6 ± 17.1 110.5 ± 18.9 118.5 ± 11.3
Mean heart rate reduction at 2 minutes (beats/min) 53.6 ± 13.2 36.8 ± 9.4 37.8 ± 10.1 34.5 ± 7.5
Reduction of peak heart rate at 2 minutes (%) 30.7 ± 7.8 24.5 ± 5.2 25.4 ± 5.4 22.5 ± 4.0
Reduction of absolute change in heart rate during exercise at 2 minutes (%) 56.6 ± 13.9 51.7 ± 10.9 53.2 ± 11.9 48.4 ± 8.0
Mean heart rate at 3 minutes (beats/min) 114.7 ± 24.1 108.6 ± 16.8 104.9 ± 16.6 116.6 ± 14.7
Mean heart rate reduction at 3 minutes (beats/min) 62.1 ± 14.5 41.2 ± 12.2 43.4 ± 12.8 36.4 ± 9.7
Reduction of peak heart rate at 3 minutes (%) 35.5 ± 8.6 27.3 ± 6.4 28.9 ± 5.9 23.8 ± 6.2
Reduction of absolute change in heart rate during exercise at 3 minutes (%) 65.7 ± 15.8 57.8 ± 13.5 60.7 ± 12.4 51.4 ± 13.9
Normalized low frequency spectral power (n.u) 0.48 ± 0.19 0.56 ± 0.18 0.55 ± 0.18 0.56 ± 0.19
Normalized high frequency spectral power (n.u) 0.51 ± 0.19 0.44 ± 0.18 0.45 ± 0.18 0.44 ± 0.19
Low:high frequency ratio 0.77 [0.53–1.93] 1.52 [0.66–2.16] 1.32 [0.68–2.14] 1.52 [0.64–2.70]

Normally distributed continuous data are expressed as mean ± SD and as median and interquartile range for non-normally distributed data.

NYHA = New York Heart Association.

p <0.05 versus controls.


p <0.05 versus nonobstructive.



The absolute recovery in HR and HRR normalized to peak HR is shown in Figure 1 . At 1 minute, the absolute reduction in HR was lower in the HC group (25.7 ± 8.4 vs 35.3 ± 11.0 beats/min, p <0.001). When normalized to peak HR, there was a trend toward a slower recovery in HR at 1 minute in the HC group (17.2 ± 5.2% vs 20.4 ± 6.8%, p = 0.052). When normalized to the change in HR from rest to peak exercise, there was no significant difference between the groups at 1 minute (36.3 ± 11.9% vs 37.7 ± 13.5%, p = 0.680). At 2 minutes, the absolute reduction in HR was lower in HC (36.8 ± 9.4 vs 53.6 ± 13.2 beats/min, p <0.001). This remained significant after normalizing to peak HR (24.5 ± 5.2% vs 30.7 ± 7.8%, p = 0.01). When normalized to the change in HR from rest and peak exercise, there was no significant difference between the groups at 2 minutes (51.7 ± 10.9% vs 56.6 ± 13.9%, p = 0.148). At 3 minutes, the absolute reduction in HR (41.2 ± 12.2 vs 62.1 ± 14.5 beats/min, p <0.001) and the reduction indexed to peak HR (27.3 ± 6.4% vs 35.5 ± 8.6%, p <0.001) were smaller in HC group. When normalized to the change in HR from rest to peak exercise, there was a trend toward a lower HRR in the HC group (57.76 ± 13.48% vs 65.67 ± 15.80%, p = 0.054).




Figure 1


(A) Absolute HRR after symptom limited cardiopulmonary exercise between control and HC groups. The change in mean absolute heart rate with time after cessation of exercise is shown, with 95% CIs calculated by the Loess function. (B) HRR normalized to peak HR after symptom limited cardiopulmonary exercise between control and HC groups. The change in mean normalized heart rate with time after cessation of exercise is shown, with 95% CIs calculated by the Loess function.


The characteristics of the cohort dichotomized according to the presence or absence of a resting left ventricular outflow tract gradient are listed in Table 1 . Resting HR was similar in both disease subgroups. Peak HR was higher in controls compared with the nonobstructive and obstructive groups. Peak oxygen capacity was higher in controls compared with the nonobstructive and obstructive patients.


The absolute HRR and HRR normalized to peak HR are shown in Figure 2 . The absolute reduction in heart rate at 1 minute was significantly lower in the nonobstructive group (26.4 ± 7.8 beats/min, p = 0.007) and the obstructive group (24.2 ± 9.6 beats/min, p = 0.005), but no difference between the nonobstructive and obstructive groups was observed (p = 1.0). At 2 minutes, the absolute reduction in HR was lower in the nonobstructive (37.8 ± 10.1 beats/min, p <0.001) and obstructive groups (34.5 ± 7.5 beats/min, p <0.001) compared with controls. No difference between the nonobstructive and obstructive groups was observed (p = 1.0). A similar trend was seen at 3 minutes with absolute HR reduction being lower in nonobstructive (43.4 ± 12.8 beats/min, p <0.001) and obstructive groups (36.4 ± 9.7 beats/min, p <0.001) versus controls. No statistical difference was observed between obstructive and nonobstructive patient groups (p = 0.327).


Dec 5, 2016 | Posted by in CARDIOLOGY | Comments Off on Heart Rate Recovery in Patients With Hypertrophic Cardiomyopathy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access